Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025
-
Park Aerospace Corp. Announces Date of Third Quarter Earnings Release and Conference Call
-
Hurco Reports Fourth Quarter and Full Year Results for Fiscal Year 2024
-
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
-
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
-
Nusano Announces Isotope Availability
-
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
-
XPPen Unveils Artist Pro 22 (Gen 2) with 2.5 K High-Performance 22-inch Drawing Display
-
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
-
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
-
Main Street Financial Services Corp. Declares Quarterly Dividend
-
Nano Labs Subsidiary Nano bit and BitFi Enter Strategic Partnership to Revolutionize Bitcoin Asset Management
-
Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress
-
Triller Saves Creators' TikTok Content Ahead of Ban
-
Breaking Stereotypes: New 3Fun Survey Reveals Media's Missteps in Polyamory Representation
-
Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
-
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
-
Pipe17 Raises Series A, Brings on First COO As Demand for AI-Powered Order Operations Takes Off
-
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
-
KORE Recognized for Connected Vehicle Innovation in 2025 IoT Breakthrough Awards Program
-
Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310
-
Diakonos Oncology to Present at Biotech Showcase 2025
-
BofA's Consumer Investments Surpasses $500 Billion in Assets as Clients Choose High-Tech, High Touch Approach to Managing Finances
-
Trumid Reports December and Full Year 2024 Trading Highlights
-
Volcon MN1 Unit Arrives at Cycle Plaza Corpus Christi, Ready to Sell
-
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
-
Barington Capital Group Files Definitive Proxy Statement for Matthews International's 2025 Annual Meeting
-
Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter
-
ESA Strengthens Leadership in Virginia's Community Solar Market with Key 2024 Milestones
-
Salesforce Unveils Agentforce for Retail to Boost Productivity with Digital Labor and Retail Cloud to Unite In-Store and Digital Shopping
-
Bank of Montreal Enters into Automatic Securities Purchase Plan
-
Shake Shack Names Justin Mennen as Chief Information and Technology Officer
-
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
-
CapsoVision's CapsoCam Plus® Capsule Endoscopy System Receives FDA Clearance for Pediatric Use, Offering a Comfortable, Child-Friendly Solution for Young Patients
-
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
-
Shakti Coin SXE Announces Entrance into the Future of Stable Digital Currency
-
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
-
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
-
Lazard to Announce Fourth-Quarter and Full-Year 2024 Financial Results
-
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
-
PAR Technology Corporation to Participate at the 27th Annual Needham Growth Conference
-
Wealth Enhancement Announces Acquisition of Danison & Associates, Inc., an Independent RIA with Over $82 Million in Client Assets
-
Enveda Welcomes Jason Kim as Chief Financial Officer
-
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
-
VIPR Solutions dominates the Lloyd’s Market with three new insurer customers
-
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformati
-
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration
-
WisdomTree Reports Monthly Metrics for December 2024
-
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development
-
Regal Rexnord Corporation to Host Fourth Quarter 2024 Earnings Conference Call on Thursday, February 6, 2025

